Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Double-blind treatment period (Part 1): To evaluate the efficacy of gantenerumab administered to patients by SC injection over 100 weeks vs. placebo on measures of cognition (ADASCog) and function (ADCS-ADL). Based on recent findings from the SCarlet RoAD study and from other studies on anti-amyloid antibodies, the study has been amended to allow for higher doses of gantenerumab to be examined in an open-label extension Open-label extension (Part 2): To evaluate the safety and tolerability of gantenerumab at higher doses (up to 1200 mg) focusing on physical and neurologic examinations, vital signs, blood safety tests, ECG, and AE monitoring
Critère d'inclusion
- MILD ALZHEIMER’S DISEASE